Pharmaceuticals, Biotechnology and Life Sciences
NEW YORK & OLORON-SAINTE-MARIE, France–(BUSINESS WIRE)–#Biotechnology–OBiS Incorporated, a New York City based healthcare and biotechnology consulting company, has announced the opening of a subsidiary office in Oloron-Sainte-Marie, France.
The pur…
NEW YORK & OLORON-SAINTE-MARIE, France–(BUSINESS WIRE)–#Biotechnology–OBiS Incorporated, a New York City based healthcare and biotechnology consulting company, has announced the opening of a subsidiary office in Oloron-Sainte-Marie, France.
The pur…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…
– TOPAZ Phase 2 interim data demonstrated proof-of-concept for apitegromab in patients with Type 2 and Type 3 spinal muscular atrophy (SMA); 12-month top-line results on-track for 2Q21
– SRK-181 DRAGON Phase 1 trial enrolling patients with solid tumo…